Exxel Pharma is focused on

• Commercialization of its FAAH inhibitor drugs and providing innovative medicines to current, unmet medical needs.
• Positioning EX937 as a novel treatment for chronic cough and a safe, non-addictive alternative to opioid drugs for pain management.
• Expanding the Company’s drug pipeline with follow-on molecules and maximizing the value of the Company’s IP portfolio.
• Achieving the goal of providing optimal returns for our investors.

Events

Exxel Pharma to Participate in New to Virtual Investor Event

Wednesday, February 5, 2024 at 4:00 PM ET

Registration Link: https://us02web.zoom.us/webinar/register/WN_jy-Ii3PyRs-YEI4gGT0NuA#/registration

Investor Relations Contact

JTC Team
Phone: 908-824-0775
Email: exxel@jtcir.com